23ANDME INC.CL.A DL-,0001 Logo
US90138Q1085
A3CSVR
ME

23ANDME INC.CL.A DL-,0001

Loading quotes...

Forecast

The analysts' average price target is €3.37 (-20.33%). The median is €3.37 (-20.33%).

Buy
  3
Hold
  1
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • 23andMe sued: accused of paying cybercriminals and covering up data leak

    California's attorney general accuses 23andMe of ignoring warning signs about suspicious login activity, failing to implement adequate security measures and not properly informing the public about a massive data leak. Investigations found that credential stuffing and a flawed relatives feature allowed access to data from around seven million customers; offers containing customer data appeared on the dark web. The suit also alleges that 23andMe secretly paid the attacker to remove damaging information from the internet and cites violations of California privacy laws. » More on heise.de

Historical dividends Dividends

All dividend metrics All metrics
In 2011, 23ANDME INC.CL.A DL-,0001 has already paid €0.00348 in dividends. The last payout was in June 2011.

Financials

In the last quarter, 23ANDME INC.CL.A DL-,0001 had revenue of €21.57m and net profit of -€20.22m
(EUR) June 2025
YoY
Revenue 21.57m -
Gross profit 11.48m -
Net profit -20.22m -
EBITDA -22.6m -

Fundamentals

Metric Value
Market capitalization
€13.89m
Number of shares
25.25m
52-week high/low
€11.58 - €0.44
Dividends No
Beta
1.20
P/E ratio
-0.06
PEG ratio
0.00
P/B ratio
-0.59
P/S ratio
0.08

Company profile

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

Name
23ANDME INC.CL.A DL-,0001
CEO
Joseph Selsavage
Headquarters South San Francisco, ca
USA
Website
Sector
Materials
Industry
Chemicals
IPO
23/11/2020
Employees 560

Ticker symbols

Exchange Symbol
NASDAQ
ME
🍪

Parqet  uses cookies. Learn more